国药控股:国药一致预计2024年归母净利润约5.61亿至7.6亿元同比下降52.48%至64.92%

新浪港股
20 Jan
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  国药控股(01099)公布,预计国药一致(000028.SZ)于2024年归属于上市公司股东的净利润为约5.61亿元-7.6亿元,同比下降52.48%-64.92%;预计扣非净利约4.97亿-6.96亿元,同比下降54.59%-67.58%。

  根据商誉减值测试初步测试结果,国药一致本次拟计提的商誉及无形资产(品牌使用权和销售网络)减值准备金额约8.76亿元至10.7亿元,预计将减少报告期内归属于上市公司股东的净利润5.05亿元至6.18亿元。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10